Deep Brain Stimulation DBS

Deep Brain Stimulation (DBS) Market Outlook

The global Deep Brain Stimulation (DBS) market is projected to reach approximately USD 3.5 billion by 2035, with a compound annual growth rate (CAGR) of around 7.8% during the forecast period from 2025 to 2035. This market growth is primarily driven by the increasing prevalence of neurological disorders, advancements in stimulation technology, and the rising awareness about DBS as a therapeutic option. Additionally, the aging population across the globe is contributing significantly to the demand for effective treatment solutions for movement disorders and mental health conditions. The growing investment in research and development activities to innovate and improve DBS devices further fuels the market expansion. Moreover, supportive government initiatives and favorable reimbursement policies are enhancing the accessibility of these advanced medical solutions.

Growth Factor of the Market

The growth of the Deep Brain Stimulation (DBS) market is predominantly influenced by the rising incidence of neurological disorders such as Parkinson's disease, dystonia, and essential tremor, which are increasingly being recognized for their debilitating effects on quality of life. Additionally, advancements in technology have led to the development of more sophisticated DBS devices that offer improved efficacy, reduced side effects, and enhanced patient comfort, thereby making the treatment more appealing to both healthcare providers and patients. The increasing adoption of DBS therapy in the management of psychiatric disorders, such as obsessive-compulsive disorder and depression, has further expanded the market's potential. Furthermore, a greater emphasis on research collaboration between academic institutions and industry stakeholders is promoting innovation in the DBS field, contributing to a more robust market landscape. Lastly, the global trend towards minimally invasive surgical techniques is favoring the uptake of DBS as a viable therapeutic option.

Key Highlights of the Market

• The market is projected to witness a CAGR of 7.8% from 2025 to 2035.
• North America dominates the market, accounting for a significant share due to advanced healthcare infrastructure.
• Technological advancements are leading to the development of more effective and safer DBS systems.
• Growing awareness and acceptance of DBS therapy for psychiatric indications is emerging as a new growth avenue.
• The presence of key market players is enhancing competition and driving innovation within the industry.

By Product Type

Single-channel DBS Systems:

Single-channel DBS systems are designed to deliver stimulation through a single electrode, targeting a specific area of the brain to alleviate symptoms associated with neurological disorders. These systems are popular due to their relatively lower costs compared to multi-channel systems, making them an attractive option for healthcare providers and patients alike. The simplicity of single-channel systems allows for easier implantation and programming, which is a significant advantage in clinical settings. Furthermore, advancements in electrode technology and stimulation patterns are enhancing the therapeutic outcomes associated with these systems, thereby supporting their continued adoption. As such, the single-channel DBS segment is expected to maintain a steady growth trajectory as more patients seek effective treatment options for conditions like Parkinson's disease and essential tremor.

Dual-channel DBS Systems:

Dual-channel DBS systems enable the delivery of stimulation through two electrodes, allowing for greater flexibility in targeting multiple areas within the brain simultaneously. This capability is particularly beneficial for patients with complex movement disorders who may require more comprehensive treatment approaches. The dual-channel systems provide clinicians with the ability to customize stimulation settings based on individual patient needs, which can lead to improved therapeutic results. Additionally, ongoing research is focused on optimizing the performance of dual-channel systems, which is expected to enhance their appeal in clinical practice. Consequently, this segment is anticipated to grow significantly as healthcare professionals increasingly recognize the advantages of multi-target stimulation in managing neurological conditions.

Rechargeable DBS Systems:

Rechargeable DBS systems are designed with battery technology that allows patients to recharge the device, reducing the frequency of battery replacement surgeries. This innovation significantly enhances patient convenience and satisfaction, as they do not need to undergo surgical procedures as often as with non-rechargeable systems. Rechargeable systems also typically offer longer battery life, allowing for continuous therapy without interruption. The increasing emphasis on patient-centered care and the desire for minimally invasive solutions have led to growing demand for rechargeable DBS systems. As manufacturers continue to improve battery technology and reduce the size of these devices, this segment is expected to expand rapidly, aligning with market trends towards more user-friendly and durable medical devices.

Non-rechargeable DBS Systems:

Non-rechargeable DBS systems are traditionally designed with batteries that require periodic replacement through surgical interventions. While these systems have been in the market for a long time, their usage is gradually declining due to the rise of rechargeable alternatives. However, non-rechargeable systems continue to serve as a viable option for certain patient populations, particularly in regions where access to rechargeable technology may be limited. The simplicity and reliability of non-rechargeable systems can still be advantageous for specific cases, particularly in acute care settings where rapid implementation is necessary. Therefore, while this segment's growth may be slower compared to rechargeable systems, it remains relevant within the market.

MRI-compatible DBS Systems:

MRI-compatible DBS systems are specifically designed to allow patients to undergo MRI scans safely, offering significant advantages in patient diagnosis and management. These systems address the previous concerns associated with traditional DBS systems, which could not be used in MRI environments due to safety risks. As MRI imaging becomes increasingly integral in diagnosing and monitoring neurological conditions, the demand for MRI-compatible DBS systems is expected to rise accordingly. The ability to perform imaging without compromising the functionality of the DBS system enhances patient care and safety. This segment is poised for significant growth, particularly as awareness of the importance of MRI compatibility increases among both patients and healthcare providers.

By Application

Parkinson's Disease:

Parkinson's disease is one of the leading applications for Deep Brain Stimulation therapy, as it significantly alleviates symptoms such as tremors, rigidity, and bradykinesia. DBS has been shown to improve the quality of life for patients who do not respond adequately to medication alone. As the prevalence of Parkinson's disease continues to rise due to aging populations, the demand for effective treatment options like DBS is also increasing. Ongoing clinical studies and trials are further solidifying the role of DBS in managing this condition. With advancements in technology adding to the efficacy and safety of DBS systems, this segment is likely to witness substantial growth in the coming years as more patients seek effective solutions for their symptoms.

Essential Tremor:

Essential tremor is another prevalent application area for DBS therapy, particularly in patients who experience severe tremors that interfere with daily activities. The effectiveness of DBS in controlling essential tremor has made it a preferred treatment option, especially for individuals who do not respond satisfactorily to pharmacological therapies. Recent advancements in DBS technology have further enhanced its efficacy in reducing tremor severity while improving the overall patient experience. As awareness about essential tremor and its impact on quality of life grows, more patients are opting for DBS as a treatment option. This trend is expected to continue, driving growth in the essential tremor segment of the market.

Dystonia:

Dystonia, characterized by involuntary muscle contractions and abnormal postures, is another key application for deep brain stimulation. DBS has been effectively utilized in treating different forms of dystonia, particularly in patients with generalized or focal dystonia who do not respond well to conservative treatments. The positive outcomes associated with DBS in managing dystonia symptoms have led to increased interest and adoption among neurologists and movement disorder specialists. As research continues to demonstrate the benefits of DBS for dystonia, including improved motor function and reduced disability, the market for this application is expected to expand significantly in the coming years.

Obsessive-Compulsive Disorder:

Obsessive-Compulsive Disorder (OCD) has recently emerged as a novel application for DBS therapy, particularly in cases where patients do not respond adequately to conventional treatment options such as cognitive-behavioral therapy and selective serotonin reuptake inhibitors. Clinical studies have shown promising results, indicating that DBS can significantly reduce compulsive behaviors and intrusive thoughts in OCD patients. As the understanding of neuropsychiatric disorders evolves, the application of DBS in treating OCD continues to gain traction. The expanding body of evidence supporting the effectiveness of DBS in this area positions it as a viable therapeutic option, leading to anticipated growth in this segment.

Epilepsy:

Epilepsy is another application area for deep brain stimulation, particularly for patients with drug-resistant epilepsy who have not achieved satisfactory seizure control through medication alone. DBS has shown potential in reducing the frequency and severity of seizures, improving the overall quality of life for these patients. As more research highlights the effectiveness of DBS in managing epilepsy, the market for this application is expected to grow. Additionally, the ongoing development of stimulation technologies that can be tailored to individual seizure patterns enhances the feasibility and attractiveness of DBS for epilepsy treatment, paving the way for increased adoption in clinical practice.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for deep brain stimulation systems, given their access to advanced medical technologies and specialized healthcare professionals. Within hospital settings, neurology and neurosurgery departments are equipped to perform the necessary assessments and procedures for DBS implantation. The comprehensive services offered in hospitals, including pre-operative evaluations and post-operative care, assure patients of a high standard of medical attention. Moreover, hospitals are often the sites for clinical trials and research studies, contributing to the advancement of DBS technology and practices. As the healthcare sector continues to evolve, hospitals are likely to remain at the forefront of DBS distribution, ensuring that patients have access to cutting-edge treatments.

Specialty Clinics:

Specialty clinics, particularly those focused on neurology and movement disorders, play an important role in the distribution of deep brain stimulation systems. These clinics often provide targeted care and expertise, catering specifically to patients with neurological conditions in need of specialized treatment options. The personalized approach offered by specialty clinics enhances patient experiences, as they can receive tailored treatment plans that address their unique needs. Furthermore, the growing number of specialty clinics is indicative of increasing recognition for the importance of specialized care in managing complex neurological disorders. As more patients seek alternatives to traditional hospital care, the specialty clinic segment is likely to experience robust growth.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are becoming increasingly popular for performing outpatient surgeries, including DBS implantation procedures. These centers offer a convenient and cost-effective setting for patients, who may prefer to avoid the extended hospital stays typically associated with surgical procedures. ASCs are equipped to provide high-quality surgical care in a less intensive environment, often resulting in quicker recovery times for patients. The trend toward outpatient surgeries is being driven by advancements in surgical techniques and anesthetic options that enable safe and efficient procedures. As this trend continues to gain traction, the ambulatory surgical center segment is expected to grow within the DBS market.

Research Institutes:

Research institutes are vital players in the distribution of deep brain stimulation systems, particularly in the context of clinical trials and experimental treatments. These institutions are often at the forefront of innovation, working to develop and validate new DBS technologies and techniques. By conducting rigorous research studies, institutes contribute to the body of knowledge surrounding the efficacy and safety of DBS in various applications. The collaboration between industry stakeholders and research institutes facilitates the rapid translation of scientific discoveries into clinical practice, ultimately benefiting patients. As the emphasis on research and development continues to rise, the role of research institutes in the DBS market is expected to expand, driving advancements in the field.

Others:

This category encompasses various distribution channels that support the availability of deep brain stimulation systems, including online platforms, distributors, and medical supply companies. As the healthcare landscape evolves, alternative distribution methods are becoming increasingly important in ensuring that patients have access to DBS technology. Online platforms streamline the procurement process for healthcare providers, while medical supply companies facilitate the distribution of devices to hospitals and clinics. Additionally, partnerships between manufacturers and distributors enhance the efficiency of product delivery, ensuring that advanced treatments are readily accessible to patients in need. This segment is anticipated to grow as more stakeholders recognize the value of diversifying distribution channels in the DBS market.

By Target Area

Subthalamic Nucleus (STN):

The subthalamic nucleus (STN) is one of the primary targets for deep brain stimulation in the treatment of movement disorders, particularly Parkinson's disease. STN stimulation has been shown to effectively reduce motor symptoms and improve overall function in patients. The anatomical location of the STN allows for modulation of the basal ganglia circuitry, leading to significant therapeutic effects. As research continues to explore the optimal parameters for STN stimulation, this target area is likely to witness sustained growth in the DBS market. The effectiveness of STN-targeted DBS for managing symptoms related to Parkinson’s disease contributes to its status as a leading target area for treatment.

Globus Pallidus (GPi):

The globus pallidus (GPi) is another critical target area for deep brain stimulation, particularly for patients with dystonia and Parkinson's disease. Stimulation of the GPi has demonstrated efficacy in reducing the severity of dystonic movements and improving motor control. Its role in the indirect pathway of the basal ganglia makes it a valuable target for modulating motor function. As clinicians continue to refine stimulation techniques and parameters for GPi-targeted DBS, the demand for this approach is expected to increase. The growing body of evidence supporting the effectiveness of GPi stimulation in various neurological conditions positions this target area as a significant segment within the DBS market.

Thalamus:

The thalamus serves as a crucial relay station for sensory and motor signals, making it an important target for deep brain stimulation. Thalamic stimulation has been primarily used in the treatment of essential tremor and certain types of epilepsy. The ability to modulate thalamic activity allows for effective control of tremors and improved seizure management. As advancements in neuromodulation techniques continue to emerge, the thalamus is likely to remain a relevant target area for DBS therapy. The segment's growth will be driven by ongoing clinical studies that highlight the efficacy of thalamic stimulation in managing various neurological disorders.

Pedunculopontine Nucleus (PPN):

The pedunculopontine nucleus (PPN) is increasingly being explored as a target area for deep brain stimulation, particularly in patients with gait disturbances associated with Parkinson's disease. Stimulation of the PPN has shown promise in improving gait and balance, two critical aspects of mobility. As researchers continue to investigate the role of PPN stimulation in enhancing motor functions, the interest in this target area is likely to grow. The potential benefits of targeting the PPN complement existing DBS therapies for Parkinson's disease, making it an exciting area of development within the market.

Others:

This category includes additional target areas explored in DBS research, such as the nucleus accumbens and the anterior cingulate cortex. While these areas have not yet gained as much prominence as the primary target sites, ongoing studies are investigating their potential for treating various neurological and psychiatric disorders. As the understanding of brain circuitry and its role in conditions like depression and addiction evolves, the exploration of alternative target areas may uncover new therapeutic opportunities. This segment represents a growing area of interest within the DBS market as researchers seek to expand the applications and efficacy of deep brain stimulation.

By Subthalamic Nucleus

Subthalamic Nucleus (Left):

Stimulation of the left subthalamic nucleus is often utilized for patients with unilateral symptoms of Parkinson's disease, particularly those experiencing significant tremors or motor dysfunction on one side of the body. Targeting the left STN allows for a more tailored approach to managing symptoms, leading to improved outcomes in patient mobility and overall quality of life. The left STN stimulation has gained favor among clinicians due to its ability to reduce side effects typically associated with bilateral stimulation. As patient awareness and acceptance of DBS therapy grow, this targeted approach is likely to gain traction in the market.

Subthalamic Nucleus (Right):

Similarly, the right subthalamic nucleus can be targeted for deep brain stimulation in patients exhibiting unilateral symptoms. By focusing on the right STN, clinicians can effectively manage motor symptoms in patients who may have a stronger response to stimulation on this side. The ability to customize stimulation based on individual patient needs is a key advantage of targeting the right STN, enhancing the overall efficacy of the treatment. As clinical evidence continues to support the effectiveness of right STN stimulation, this segment is expected to see growth as more patients seek tailored therapeutic solutions through DBS.

By Globus Pallidus

Globus Pallidus Internus (GPi):

The globus pallidus internus (GPi) is a primary target for deep brain stimulation in the treatment of movement disorders, particularly dystonia and Parkinson's disease. Targeting the GPi allows clinicians to modulate the output of the basal ganglia, leading to improved motor control and reduced symptoms. Recent studies have highlighted the efficacy of GPi stimulation in managing dystonic movements, often resulting in significant improvements in patient quality of life. As more patients seek alternatives to conventional therapies, the GPi segment is expected to witness continued growth, bolstered by ongoing research that supports its clinical applications.

Globus Pallidus Externus (GPe):

The globus pallidus externus (GPe) is an emerging target for deep brain stimulation, with ongoing research exploring its potential benefits for various movement disorders. Although less commonly targeted than the GPi, the GPe's role in the basal ganglia circuitry makes it a compelling area of investigation. Initial studies suggest that GPe stimulation may help alleviate symptoms in some patients with Parkinson's disease and other movement disorders. As the understanding of GPe's function within the basal ganglia deepens, this segment may gain more attention, leading to its potential incorporation into clinical practice.

By Pedunculopontine Nucleus

Pedunculopontine Nucleus (PPN):

The pedunculopontine nucleus (PPN) is being increasingly recognized as a valuable target for deep brain stimulation in patients with Parkinson's disease. Stimulation of the PPN has demonstrated potential benefits in improving gait and balance, addressing two critical challenges faced by patients. As clinical studies continue to explore the effectiveness of PPN stimulation, awareness of its therapeutic potential is likely to grow. This segment represents a promising area of development within the DBS market, as more patients seek solutions for gait disturbances and related mobility issues.

Others:

In addition to the main target areas, there are other nuclei and regions being studied for their potential in deep brain stimulation. These may include lesser-known structures that have shown promise in preclinical or early clinical investigations. As the field of DBS continues to evolve, ongoing research is expected to provide insights into the benefits of targeting these additional areas, potentially expanding the applications of DBS therapy and enhancing its effectiveness in treating various neurological and psychiatric disorders.

By Region

The Deep Brain Stimulation (DBS) market is characterized by significant regional variations, driven by differences in healthcare infrastructure, prevalence of neurological disorders, and regulatory environments. North America holds a dominant position in the DBS market, accounting for approximately 45% of the global share in 2025. This dominance can be attributed to advanced healthcare systems, high awareness levels among patients and providers, and substantial investments in research and development. The region is also characterized by a growing aging population, which contributes to the rising prevalence of conditions commonly treated with DBS, such as Parkinson's disease and essential tremor. North America's market is projected to grow at a CAGR of 8.5%, supported by ongoing technological advancements and increasing collaboration between medical device manufacturers and healthcare providers.

Europe follows North America in market share, accounting for around 30% of the global DBS market in 2025. The European market benefits from a robust healthcare infrastructure, comprehensive healthcare policies, and a high prevalence of neurological disorders. Countries such as Germany, France, and the UK are leading contributors to the market growth due to their established healthcare systems and increasing investment in neuromodulation technologies. The Asia Pacific region is expected to witness the highest growth rate, with a CAGR of 9.2%, driven by rising awareness of advanced treatment options and growing healthcare expenditures. The expanding patient population and improving access to healthcare facilities are likely to enhance the adoption of DBS therapy in this region. Overall, the regional dynamics within the DBS market reflect a diverse landscape of opportunities and challenges, influencing the strategies employed by key players.

Opportunities

The Deep Brain Stimulation (DBS) market is poised to benefit from numerous opportunities, particularly as new technological advancements continue to emerge. One significant opportunity lies in the development of next-generation DBS systems that incorporate wireless technology, enabling remote monitoring and adjustments. This innovation can significantly enhance patient experience and adherence to therapy, as clinicians can make adjustments without the need for frequent hospital visits. Furthermore, the growing trend of personalized medicine is driving research efforts to tailor DBS therapy based on individual patient characteristics, leading to improved treatment outcomes. The potential to expand the applications of DBS beyond movement disorders, such as its use in psychiatric conditions like depression, presents another exciting opportunity for market growth and diversification.

Additionally, the increasing number of clinical trials exploring the efficacy of DBS in various neurological and psychiatric conditions is indicative of the growing interest in this technology. As more positive outcomes are reported, healthcare providers may become more inclined to adopt DBS as a treatment option for a broader range of disorders. The expansion of reimbursement policies supporting DBS procedures can also enhance accessibility and affordability for patients, further driving market growth. Companies that invest in research and development to innovate and improve DBS technologies are likely to capitalize on these opportunities, positioning themselves for success in an evolving market landscape.

Threats

The Deep Brain Stimulation (DBS) market faces several threats that could impact its growth trajectory. One of the major concerns is the potential for adverse effects associated with the procedure, such as infection, bleeding, or neurological complications. These risks may deter some patients from opting for DBS therapy, particularly those with pre-existing conditions that increase the likelihood of surgical complications. Furthermore, the relatively high cost of DBS systems and the associated surgical procedures can limit access for certain patient populations, particularly in developing regions. The lack of insurance coverage for DBS in some areas can also impede market growth, as patients may be unwilling or unable to bear the out-of-pocket expenses.

In addition to these challenges, the competitive landscape within the medical device industry is evolving rapidly, with new entrants and innovative technologies emerging frequently. Established companies must continually innovate to maintain their market share, which can strain resources and lead to increased operational costs. The complexity of regulatory approval processes for new DBS devices can also pose challenges for manufacturers, delaying product launches and hindering market entry. As the DBS market continues to grow, stakeholders must navigate these threats while focusing on delivering safe, effective, and accessible solutions for patients in need.

Competitor Outlook

• Med

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Med
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Deep Brain Stimulation DBS Market, By Application
    • 6.1.1 Parkinson's Disease
    • 6.1.2 Essential Tremor
    • 6.1.3 Dystonia
    • 6.1.4 Obsessive-Compulsive Disorder
    • 6.1.5 Epilepsy
  • 6.2 Deep Brain Stimulation DBS Market, By Target Area
    • 6.2.1 Subthalamic Nucleus (STN)
    • 6.2.2 Globus Pallidus (GPi)
    • 6.2.3 Thalamus
    • 6.2.4 Pedunculopontine Nucleus (PPN)
    • 6.2.5 Others
  • 6.3 Deep Brain Stimulation DBS Market, By Product Type
    • 6.3.1 Single-channel DBS Systems
    • 6.3.2 Dual-channel DBS Systems
    • 6.3.3 Rechargeable DBS Systems
    • 6.3.4 Non-rechargeable DBS Systems
    • 6.3.5 MRI-compatible DBS Systems
  • 6.4 Deep Brain Stimulation DBS Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Specialty Clinics
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Research Institutes
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Deep Brain Stimulation DBS Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Deep Brain Stimulation DBS market is categorized based on

By Product Type

• Single-channel DBS Systems
• Dual-channel DBS Systems
• Rechargeable DBS Systems
• Non-rechargeable DBS Systems
• MRI-compatible DBS Systems

By Application

• Parkinson's Disease
• Essential Tremor
• Dystonia
• Obsessive-Compulsive Disorder
• Epilepsy

By Distribution Channel

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Research Institutes
• Others

By Target Area

• Subthalamic Nucleus (STN)
• Globus Pallidus (GPi)
• Thalamus
• Pedunculopontine Nucleus (PPN)
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Med